In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Though prescribing climate-friendly dry powder inhalers is environmentally sound, some experts warn certain patients may be ...

Theravance Biopharma ( (TBPH) ) has released its Q3 earnings. Here is a breakdown of the information Theravance Biopharma presented to its ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

The KSE-100 index of Pakistan Stock Exchange (PSX) lost on Tuesday more than 400 points, weighed down by institutional profit ...

Think AstraZeneca (AZN.L), GSK (GSK.L), Rolls-Royce (RR.L ... This was mainly driven by an 18.1% boost in subscription revenue, the core of the company’s business. Earnings per share (EPS) beat ...

CureVac NV (CVAC) reports robust revenue growth and strategic advancements in oncology, despite ongoing litigation challenges.

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 30-09-2024, ...

The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 ...